APO Research
Talk to an analyst

APO RESEARCH · REPORT

Daratumumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Daratumumab Market Outlook and Growth Opportunities 2026

23 December 2025194 pages

Choose your research edition.

Industry ResearchDaratumumab Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Daratumumab Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Daratumumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Daratumumab Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Daratumumab Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Daratumumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Daratumumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Daratumumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Daratumumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Daratumumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Daratumumab market include Johnson＆Johnson. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Daratumumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Daratumumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Daratumumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Daratumumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Daratumumab Segment by Company

Johnson＆Johnson

Daratumumab Segment by Type

100mg Injection

400mg Injection

Daratumumab Segment by Application

Multiple Myeloma

Follicular Lymphoma

Diffuse Large B Cell Lymphoma

Mantle Cell Lymphoma

Others

Daratumumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Daratumumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Daratumumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Daratumumab significant trends, drivers, influence factors in global and regions.

6. To analyze Daratumumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Daratumumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Daratumumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Daratumumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Daratumumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Daratumumab industry.

Chapter 3: Detailed analysis of Daratumumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Daratumumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Daratumumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Daratumumab Industry Trends Table 2. Daratumumab Industry Drivers Table 3. Daratumumab Industry Opportunities and Challenges Table 4. Daratumumab Industry Restraints Table 5. Global Daratumumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Daratumumab Revenue Share by Company (2021-2026) Table 7. Global Daratumumab Sales Volume by Company (k units) & (2021-2026) Table 8. Global Daratumumab Sales Volume Share by Company (2021-2026) Table 9. Global Daratumumab Average Price (US$/unit) of Company (2021-2026) Table 10. Global Daratumumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Daratumumab Key Company Manufacturing Base & Headquarters Table 12. Global Daratumumab Company, Product Type & Application Table 13. Global Daratumumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Daratumumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg Injection Table 18. Significant Companies of 400mg Injection Table 19. Global Daratumumab Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Daratumumab Sales Volume by Type (2021-2026) & (k units) Table 21. Global Daratumumab Sales Volume by Type (2027-2032) & (k units) Table 22. Global Daratumumab Sales Volume Share by Type (2021-2026) Table 23. Global Daratumumab Sales Volume Share by Type (2027-2032) Table 24. Global Daratumumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Daratumumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Daratumumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Daratumumab Sales Value Share by Type (2021-2026) Table 28. Global Daratumumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Multiple Myeloma Table 30. Significant Companies of Follicular Lymphoma Table 31. Significant Companies of Diffuse Large B Cell Lymphoma Table 32. Significant Companies of Mantle Cell Lymphoma Table 33. Significant Companies of Others Table 34. Global Daratumumab Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Daratumumab Sales Volume by Application (2021-2026) & (k units) Table 36. Global Daratumumab Sales Volume by Application (2027-2032) & (k units) Table 37. Global Daratumumab Sales Volume Share by Application (2021-2026) Table 38. Global Daratumumab Sales Volume Share by Application (2027-2032) Table 39. Global Daratumumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Daratumumab Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Daratumumab Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Daratumumab Sales Value Share by Application (2021-2026) Table 43. Global Daratumumab Sales Value Share by Application (2027-2032) Table 44. Global Daratumumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Daratumumab Sales by Region (2021-2026) & (k units) Table 46. Global Daratumumab Sales Market Share by Region (2021-2026) Table 47. Global Daratumumab Sales by Region (2027-2032) & (k units) Table 48. Global Daratumumab Sales Market Share by Region (2027-2032) Table 49. Global Daratumumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Daratumumab Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Daratumumab Sales Value Share by Region (2021-2026) Table 52. Global Daratumumab Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Daratumumab Sales Value Share by Region (2027-2032) Table 54. Global Daratumumab Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Daratumumab Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Daratumumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Daratumumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Daratumumab Sales by Country (2021-2026) & (k units) Table 59. Global Daratumumab Sales Market Share by Country (2021-2026) Table 60. Global Daratumumab Sales by Country (2027-2032) & (k units) Table 61. Global Daratumumab Sales Market Share by Country (2027-2032) Table 62. Global Daratumumab Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Daratumumab Sales Value Market Share by Country (2021-2026) Table 64. Global Daratumumab Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Daratumumab Sales Value Market Share by Country (2027-2032) Table 66. Johnson＆Johnson Company Information Table 67. Johnson＆Johnson Business Overview Table 68. Johnson＆Johnson Daratumumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Johnson＆Johnson Daratumumab Product Portfolio Table 70. Johnson＆Johnson Recent Development Table 71. Key Raw Materials Table 72. Raw Materials Key Suppliers Table 73. Daratumumab Distributors List Table 74. Daratumumab Customers List Table 75. Research Programs/Design for This Report Table 76. Authors List of This Report Table 77. Secondary Sources Table 78. Primary Sources List of Figures Figure 1. Daratumumab Product Image Figure 2. Global Daratumumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Daratumumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Daratumumab Sales (2021-2032) & (k units) Figure 5. Global Daratumumab Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Daratumumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg Injection Image Figure 10. 400mg Injection Image Figure 11. Global Daratumumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Daratumumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Daratumumab Sales Volume Share by Type (2021-2032) Figure 14. Global Daratumumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Daratumumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Daratumumab Sales Value Share by Type (2021-2032) Figure 17. Multiple Myeloma Image Figure 18. Follicular Lymphoma Image Figure 19. Diffuse Large B Cell Lymphoma Image Figure 20. Mantle Cell Lymphoma Image Figure 21. Others Image Figure 22. Global Daratumumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Daratumumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Daratumumab Sales Volume Share by Application (2021-2032) Figure 25. Global Daratumumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Daratumumab Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Daratumumab Sales Value Share by Application (2021-2032) Figure 28. Global Daratumumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Daratumumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Daratumumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Daratumumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Daratumumab Sales Value (2021-2032) & (US$ Million) Figure 33. North America Daratumumab Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Daratumumab Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Daratumumab Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Daratumumab Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Daratumumab Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Daratumumab Sales Value (2021-2032) & (US$ Million) Figure 39. South America Daratumumab Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Daratumumab Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Daratumumab Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Daratumumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Daratumumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Daratumumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Daratumumab Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Daratumumab Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg Injection
  • 400mg Injection
Applications
  • Multiple Myeloma
  • Follicular Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Mantle Cell Lymphoma
  • Others
Companies covered
  • Johnson＆Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Daratumumab Sales Value (2021-2032)
  4. 1.2.2 Global Daratumumab Sales Volume (2021-2032)
  5. 1.2.3 Global Daratumumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Daratumumab Market Dynamics
  1. 2.1 Daratumumab Industry Trends
  2. 2.2 Daratumumab Industry Drivers
  3. 2.3 Daratumumab Industry Opportunities and Challenges
  4. 2.4 Daratumumab Industry Restraints
3 Daratumumab Market by Company
  1. 3.1 Global Daratumumab Company Revenue Ranking in 2025
  2. 3.2 Global Daratumumab Revenue by Company (2021-2026)
  3. 3.3 Global Daratumumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Daratumumab Average Price by Company (2021-2026)
  5. 3.5 Global Daratumumab Company Ranking (2024-2026)
  6. 3.6 Global Daratumumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Daratumumab Company Product Type and Application
  8. 3.8 Global Daratumumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Daratumumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Daratumumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Daratumumab Market by Type
  1. 4.1 Daratumumab Type Introduction
  2. 4.1.1 100mg Injection
  3. 4.1.2 400mg Injection
  4. 4.2 Global Daratumumab Sales Volume by Type
  5. 4.2.1 Global Daratumumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Daratumumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Daratumumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Daratumumab Sales Value by Type
  9. 4.3.1 Global Daratumumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Daratumumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Daratumumab Sales Value Share by Type (2021-2032)
5 Daratumumab Market by Application
  1. 5.1 Daratumumab Application Introduction
  2. 5.1.1 Multiple Myeloma
  3. 5.1.2 Follicular Lymphoma
  4. 5.1.3 Diffuse Large B Cell Lymphoma
  5. 5.1.4 Mantle Cell Lymphoma
  6. 5.1.5 Others
  7. 5.2 Global Daratumumab Sales Volume by Application
  8. 5.2.1 Global Daratumumab Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Daratumumab Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Daratumumab Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Daratumumab Sales Value by Application
  12. 5.3.1 Global Daratumumab Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Daratumumab Sales Value by Application (2021-2032)
  14. 5.3.3 Global Daratumumab Sales Value Share by Application (2021-2032)
6 Daratumumab Regional Sales and Value Analysis
  1. 6.1 Global Daratumumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Daratumumab Sales by Region (2021-2032)
  3. 6.2.1 Global Daratumumab Sales by Region: 2021-2026
  4. 6.2.2 Global Daratumumab Sales by Region (2027-2032)
  5. 6.3 Global Daratumumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Daratumumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Daratumumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Daratumumab Sales Value by Region (2027-2032)
  9. 6.5 Global Daratumumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Daratumumab Sales Value (2021-2032)
  12. 6.6.2 North America Daratumumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Daratumumab Sales Value (2021-2032)
  15. 6.7.2 Europe Daratumumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Daratumumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Daratumumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Daratumumab Sales Value (2021-2032)
  21. 6.9.2 South America Daratumumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Daratumumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Daratumumab Sales Value Share by Country, 2025 VS 2032
7 Daratumumab Country-level Sales and Value Analysis
  1. 7.1 Global Daratumumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Daratumumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Daratumumab Sales by Country (2021-2032)
  4. 7.3.1 Global Daratumumab Sales by Country (2021-2026)
  5. 7.3.2 Global Daratumumab Sales by Country (2027-2032)
  6. 7.4 Global Daratumumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Daratumumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Daratumumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Daratumumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Daratumumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Daratumumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Daratumumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Daratumumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Daratumumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Daratumumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Daratumumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Daratumumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Daratumumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Daratumumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Daratumumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Daratumumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Daratumumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Daratumumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Daratumumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Daratumumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Daratumumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Daratumumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Daratumumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Daratumumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Daratumumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Daratumumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Daratumumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Daratumumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Daratumumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Daratumumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Daratumumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Daratumumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Daratumumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Daratumumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Daratumumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Daratumumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Daratumumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Daratumumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Daratumumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Daratumumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Daratumumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Daratumumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Daratumumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Daratumumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Daratumumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Daratumumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Daratumumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Daratumumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Daratumumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Daratumumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Daratumumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Daratumumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Daratumumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Daratumumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Daratumumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Daratumumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Daratumumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Daratumumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Daratumumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Daratumumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Daratumumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Daratumumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Daratumumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Daratumumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Daratumumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Daratumumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Daratumumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Daratumumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Daratumumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Daratumumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Daratumumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Daratumumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Daratumumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Daratumumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Daratumumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Daratumumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Daratumumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Daratumumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Daratumumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Daratumumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Daratumumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Daratumumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Daratumumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Daratumumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Daratumumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Daratumumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Daratumumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson＆Johnson
  2. 8.1.1 Johnson＆Johnson Company Information
  3. 8.1.2 Johnson＆Johnson Business Overview
  4. 8.1.3 Johnson＆Johnson Daratumumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson＆Johnson Daratumumab Product Portfolio
  6. 8.1.5 Johnson＆Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Daratumumab Value Chain Analysis
  2. 9.1.1 Daratumumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Daratumumab Sales Mode & Process
  6. 9.2 Daratumumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Daratumumab Distributors
  9. 9.2.3 Daratumumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst